Doctors sometimes inject a drug not to make you better, but to watch what happens next. These are diagnostic drugs — medications administered specifically to provoke, reveal, or confirm a medical condition rather than treat it. The most well-known historical example is edrophonium, marketed as Tensilon, which was the gold standard for diagnosing myasthenia gravis from the 1930s until the FDA discontinued it in 2018. When injected intravenously, edrophonium temporarily improved muscle strength within seconds in patients who had the disease, effectively confirming the diagnosis on the spot. The drug did nothing to cure myasthenia gravis. It simply unmasked it.
This practice — using a pharmaceutical agent as a diagnostic tool — spans nearly every specialty in medicine, from cardiology to endocrinology to neurology. A 2025 article in the *National Journal of Pharmacology and Therapeutics* formally defines the field of diagnostic pharmacology: these drugs interact with specific receptors or biological pathways to reveal physiological dysfunction, enhancing the sensitivity and specificity of clinical tests without providing any treatment. The concept is older than most people realize. Insulin was first used diagnostically in the early twentieth century through the insulin tolerance test, which revealed adrenal insufficiency long before modern blood panels existed. This article covers the classic diagnostic drugs still in use today, how pharmacologic stress tests work for heart disease, what recent breakthroughs mean for Alzheimer’s diagnosis, and the limitations and risks that come with using drugs as detective tools rather than therapies. Whether you are a caregiver navigating a loved one’s diagnostic workup or simply trying to understand why a doctor ordered a test that involves an injection rather than a blood draw, the answers are here.
Table of Contents
- What Drugs Do Doctors Use to Confirm a Diagnosis Instead of Treating a Disease?
- How Pharmacologic Stress Tests Use Drugs to Diagnose Heart Disease
- Contrast Agents — The Invisible Diagnostic Drugs Hiding in Every Scan
- The Tensilon Test — A Cautionary Tale About Diagnostic Drugs That Outlive Their Usefulness
- Risks and Limitations of Using Drugs as Diagnostic Tools
- How Naloxone Serves as Both Diagnosis and Treatment in One Injection
- New Frontiers — Blood Tests and Imaging Agents Reshaping Alzheimer’s Diagnosis
- Conclusion
- Frequently Asked Questions
What Drugs Do Doctors Use to Confirm a Diagnosis Instead of Treating a Disease?
The list is longer than most patients expect. Cosyntropin, a synthetic version of the hormone ACTH, is injected during the ACTH stimulation test to diagnose adrenal insufficiency, commonly known as Addison’s disease. A shot of cosyntropin is given, and then blood cortisol levels are measured at timed intervals afterward. If the adrenal glands fail to respond with a sufficient cortisol surge, the diagnosis is confirmed. According to data reviewed by the Cleveland Clinic and StatPearls, this test has 97 percent sensitivity at 95 percent specificity for primary adrenal insufficiency, though the numbers drop to 57 to 61 percent sensitivity for secondary adrenal insufficiency — meaning the test is far better at catching problems that originate in the adrenal glands themselves than those caused by pituitary dysfunction. Secretin, a naturally occurring hormone, serves a similar unmasking role in gastroenterology. The secretin stimulation test is used to diagnose Zollinger-Ellison syndrome, a condition caused by gastrin-secreting tumors called gastrinomas, as well as to evaluate chronic pancreatitis.
When secretin is administered, patients with gastrinomas show a paradoxical spike in gastrin levels, which healthy patients do not. Sensitivity for detecting chronic pancreatitis ranges from 60 to 94 percent, with specificity between 67 and 95 percent, according to MedlinePlus and the National Cancer Institute. Metoclopramide, typically known as an anti-nausea drug, also has a diagnostic application: the metoclopramide challenge test enhances gastric motility to help diagnose gastroparesis, a condition where the stomach empties too slowly. Then there is naloxone, which occupies a unique middle ground. When administered to a patient in a suspected opioid overdose, naloxone serves as both a diagnostic and therapeutic agent simultaneously. If the patient rapidly improves after receiving naloxone, it confirms that opioids were the cause of the respiratory depression — often before lab toxicology results have come back. In emergency departments, this dual role makes naloxone one of the fastest diagnostic confirmations in all of medicine.
How Pharmacologic Stress Tests Use Drugs to Diagnose Heart Disease
One of the most common diagnostic drug applications that patients encounter is the pharmacologic cardiac stress test. For patients who cannot walk on a treadmill — due to arthritis, injury, severe deconditioning, or other physical limitations — doctors use adenosine or regadenoson to chemically simulate the effects of exercise on the heart. These agents dilate the coronary arteries, and when combined with imaging, they reveal areas of reduced blood flow that indicate coronary artery disease. The drug is not treating the heart disease. It is making the disease visible so doctors can see where blockages or narrowing exist. However, pharmacologic stress tests are not without limitations. Patients with severe asthma or significant bronchospastic disease may not be candidates for adenosine-based protocols because these drugs can trigger dangerous airway constriction.
Regadenoson was developed as a more selective alternative with fewer respiratory side effects, but it still carries warnings. Side effects during the test can include flushing, headache, chest tightness, and transient drops in blood pressure. For some patients, the experience is uncomfortable enough that they describe it as feeling like an elephant sitting on their chest for thirty to sixty seconds. The discomfort passes quickly, but patients should be warned in advance so they do not panic and confuse the expected drug effect with an actual cardiac event. The critical distinction for patients and caregivers to understand is this: a pharmacologic stress test diagnoses coronary artery disease, but it does not open any arteries or fix any blockages. If the test reveals significant disease, further intervention — such as catheterization, stenting, or surgical bypass — is a separate conversation entirely. The diagnostic drug is the flashlight, not the repair kit.
Contrast Agents — The Invisible Diagnostic Drugs Hiding in Every Scan
Most patients do not think of contrast agents as drugs, but substances like iodine-based contrast for CT scans, gadolinium for MRI, and barium sulfate for fluoroscopic imaging are administered to patients for a purely diagnostic purpose. They have no therapeutic effect whatsoever. Their job is to improve visualization of blood vessels, organs, tumors, and other structures so that radiologists can confirm or rule out a diagnosis. According to RadiologyInfo.org and the Merck Manual, these agents are among the most frequently administered diagnostic substances in all of medicine. Millions of doses are given every year. Yet they carry real risks.
Iodine-based contrast can cause allergic reactions ranging from mild hives to life-threatening anaphylaxis, and it poses a risk of contrast-induced nephropathy in patients with compromised kidney function. Gadolinium, once considered inert, has come under scrutiny after reports of gadolinium deposition disease — a condition where the metal accumulates in the brain and other tissues after repeated MRI scans. Patients with severe kidney disease face the additional risk of nephrogenic systemic fibrosis from gadolinium exposure, a potentially fatal condition that causes hardening and thickening of the skin and connective tissues. For older adults being evaluated for cognitive decline, this matters directly. MRI with gadolinium contrast is commonly used in dementia workups to rule out tumors, strokes, or structural abnormalities that could be mimicking Alzheimer’s disease. Caregivers should ensure that the ordering physician is aware of any history of kidney disease or prior contrast reactions before the scan is scheduled. The diagnostic benefit almost always outweighs the risk, but the risk is not zero, and informed consent requires that patients and families understand what is being injected and why.
The Tensilon Test — A Cautionary Tale About Diagnostic Drugs That Outlive Their Usefulness
For decades, the Tensilon test was the textbook example of a diagnostic drug in action. A patient suspected of having myasthenia gravis would receive an intravenous injection of edrophonium chloride. If the patient’s drooping eyelids lifted and muscle weakness temporarily improved — sometimes within thirty seconds — the diagnosis was essentially confirmed. It was dramatic, fast, and easy to interpret. Medical students learned about it in their first year of pharmacology. Then the FDA pulled it.
In 2018, edrophonium was discontinued in the United States due to concerns about false positive results and the availability of superior antibody-based blood tests that could diagnose myasthenia gravis with greater accuracy and without the risks of an intravenous drug challenge. The Tensilon test could produce misleading results in patients with other neuromuscular conditions, and it carried risks of its own — bradycardia, bronchospasm, and in rare cases, cardiac arrest. Modern acetylcholine receptor antibody testing and repetitive nerve stimulation studies have largely replaced it. The Tensilon story is worth knowing because it illustrates a broader truth about diagnostic pharmacology: these tools are only valuable as long as they remain more accurate and safer than the alternatives. When a blood test or imaging advance can achieve the same diagnostic certainty without injecting a drug that carries side effects, the drug gets retired. Patients and caregivers should never assume that a diagnostic drug test is the only option. It is always reasonable to ask whether a less invasive alternative exists, especially for elderly patients who may be more vulnerable to adverse reactions.
Risks and Limitations of Using Drugs as Diagnostic Tools
The 2025 *National Journal of Pharmacology and Therapeutics* review highlights several challenges inherent to diagnostic pharmacology that patients and families should understand. First, adverse reactions are possible with any diagnostic drug, just as they are with therapeutic medications. The difference is that a patient taking a treatment drug accepts the risk because the drug is managing a condition. With a diagnostic drug, the patient is accepting risk purely for the sake of information — a calculus that demands careful informed consent. Second, false results remain a persistent problem. The ACTH stimulation test, for all its reliability in primary adrenal insufficiency, catches only about 57 to 61 percent of cases of secondary adrenal insufficiency.
That means roughly four out of ten patients with pituitary-driven adrenal failure could receive a normal result and be falsely reassured. Similarly, the secretin stimulation test’s sensitivity for chronic pancreatitis varies so widely — 60 to 94 percent depending on the study — that a negative result cannot definitively rule out the disease. Doctors must interpret diagnostic drug tests within the full clinical picture, not as standalone verdicts. Third, many of these tests require specialized equipment, trained personnel, and sometimes an intensive care setting nearby in case of severe reactions. This means they are not available at every clinic or urgent care facility, and scheduling delays can extend the diagnostic timeline by weeks. For elderly patients with progressive cognitive symptoms, where time matters and anxiety runs high, these delays are more than an inconvenience — they are a genuine burden on both patient and caregiver. Always ask the ordering physician what the test involves, where it will be performed, and what the contingency plan is if something goes wrong during the procedure.
How Naloxone Serves as Both Diagnosis and Treatment in One Injection
Naloxone deserves special attention because it collapses the usual boundary between diagnostic and therapeutic drugs. In an emergency department or in the field, when a patient presents with pinpoint pupils, respiratory depression, and altered consciousness, paramedics or emergency physicians administer naloxone without waiting for confirmatory lab work. If the patient wakes up and starts breathing normally within minutes, the opioid overdose diagnosis is confirmed retroactively by the drug’s effect.
If nothing happens, clinicians move on to investigate other causes — poisoning by non-opioid substances, stroke, metabolic emergencies, or head trauma. This diagnostic-by-treatment approach works because naloxone is fast-acting, has a well-understood mechanism, and carries minimal risk when given to someone who is not actually experiencing an opioid overdose. It is one of the rare situations in medicine where giving the drug first and asking questions later is considered the standard of care. For families dealing with a loved one’s substance use, understanding that naloxone is both a lifesaving treatment and an immediate diagnostic confirmation can reduce the fear and confusion that surrounds overdose emergencies.
New Frontiers — Blood Tests and Imaging Agents Reshaping Alzheimer’s Diagnosis
The most significant recent development in diagnostic pharmacology for brain health is not a drug injection at all — it is a blood test. The FDA has cleared the first blood-based in vitro diagnostic for Alzheimer’s disease, which measures the ratio of phosphorylated tau (p-Tau217) to beta-amyloid 1-42 in blood plasma. This test is approved for patients aged 55 and older who present with cognitive impairment, and it represents a seismic shift away from the invasive, expensive lumbar punctures and PET scans that have historically been required to confirm amyloid pathology in the brain.
On the imaging side, Neuraceq (florbetaben), an amyloid PET imaging agent, received FDA expansion of its indications to enhance Alzheimer’s diagnosis. And in oncology, ITM-94 received FDA fast track designation as a diagnostic agent for detecting clear cell renal cell carcinoma in patients with indeterminate kidney masses, with Phase 1/2 trials currently underway. These developments point toward a future where diagnostic agents become more targeted, less invasive, and more widely accessible. For the millions of families watching a loved one’s cognition decline and wondering whether it is Alzheimer’s or something else, the arrival of a reliable blood-based biomarker test may be the single most important diagnostic advance in a generation.
Conclusion
Diagnostic drugs occupy a strange and often misunderstood corner of medicine. They are prescribed not to heal, but to reveal. From the now-retired Tensilon test for myasthenia gravis to the cosyntropin challenge for adrenal insufficiency to the adenosine stress test for coronary artery disease, these agents have helped physicians confirm diagnoses that imaging and blood work alone could not settle. They carry real risks — adverse reactions, false results, and the burden of specialized testing environments — but when used appropriately, they provide clarity that changes the course of treatment.
For families navigating a dementia diagnosis, the landscape is shifting fast. The plasma p-tau 217 blood test and expanded amyloid PET imaging agents are moving Alzheimer’s confirmation from the realm of exclusion-based guesswork toward genuine biomarker-driven certainty. If a doctor recommends a diagnostic drug test or agent for your loved one, ask what it will reveal, what the risks are, whether a less invasive alternative exists, and how the result will change the treatment plan. A drug that confirms a diagnosis is only as valuable as the action it enables.
Frequently Asked Questions
What is a diagnostic drug?
A diagnostic drug is a medication given not to treat a disease but to provoke or reveal a physiological response that confirms or rules out a specific medical condition. Examples include cosyntropin for adrenal insufficiency and adenosine for coronary artery disease testing.
Why was the Tensilon test discontinued?
The FDA discontinued edrophonium (Tensilon) in 2018 because of concerns about false positive results and the availability of more accurate antibody-based blood tests for myasthenia gravis that did not require an intravenous drug challenge.
Are diagnostic drugs safe for elderly patients?
Most diagnostic drugs are considered safe when administered in appropriate clinical settings, but elderly patients may face higher risks of adverse reactions, particularly with contrast agents in patients who have kidney disease. The ordering physician should be informed of all pre-existing conditions.
Is there now a blood test for Alzheimer’s disease?
Yes. The FDA has cleared a blood-based diagnostic that measures the ratio of phosphorylated tau (p-Tau217) to beta-amyloid 1-42 in blood plasma. It is approved for patients aged 55 and older who present with cognitive impairment.
Can naloxone be used to diagnose an opioid overdose?
Yes. Naloxone functions as both a diagnostic and therapeutic agent. If a patient with suspected opioid overdose rapidly improves after receiving naloxone, it confirms that opioids were the cause of the symptoms, often before lab results are available.
What is the ACTH stimulation test?
The ACTH stimulation test uses cosyntropin, a synthetic form of ACTH, to evaluate whether the adrenal glands are producing enough cortisol. It has 97 percent sensitivity and 95 percent specificity for primary adrenal insufficiency, though it is less reliable for secondary adrenal insufficiency caused by pituitary dysfunction.
